File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma

TitleGenomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma
Authors
Issue Date2007
PublisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/bmm
Citation
Biomarkers in Medicine, 2007, v. 1 n. 2, p. 273-284 How to Cite?
AbstractHepatocellular carcinoma is one of the most deadly liver malignancies found worldwide, with hepatitis virus infection being the prominent risk factor for this lesion. Patients with hepatocellular carcinoma are usually first diagnosed when in the advanced stage; thus, long-term clinical outcomes are poor and patients have limited treatment options. Currently, surveillance of hepatocellular carcinoma relies upon serological testing of alpha-fetoprotein levels and hepatic ultrasonography, which have low sensitivity and specificity, and are sometimes operator-dependent, respectively. Therefore, discovery of new biomarkers for early and accurate detection of hepatocellular carcinoma would be of great clinical value. Genomic and proteomic approaches are two major laboratory platforms for the identification of candidate hepatocellular carcinoma biomarkers based on profiling and validating with tumor and nontumor clinical samples. Frequently, these diagnostic markers have been found in association with genetic aberrations, protein-level alterations, post-translational modifications and immune functions. With the discovery of these biomarkers, earlier detection of hepatocellular carcinoma in high-risk subjects (e.g., cirrhosis and hepatitis carriers) becomes possible, which will enable clinicians to offer patients better clinical management and more effective treatment modalities.
Persistent Identifierhttp://hdl.handle.net/10722/84314
ISSN
2015 Impact Factor: 2.179
2015 SCImago Journal Rankings: 0.834
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLee, NPYen_HK
dc.contributor.authorCheung, STen_HK
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorLuk, JMCen_HK
dc.date.accessioned2010-09-06T08:51:28Z-
dc.date.available2010-09-06T08:51:28Z-
dc.date.issued2007en_HK
dc.identifier.citationBiomarkers in Medicine, 2007, v. 1 n. 2, p. 273-284en_HK
dc.identifier.issn1752-0363en_HK
dc.identifier.urihttp://hdl.handle.net/10722/84314-
dc.description.abstractHepatocellular carcinoma is one of the most deadly liver malignancies found worldwide, with hepatitis virus infection being the prominent risk factor for this lesion. Patients with hepatocellular carcinoma are usually first diagnosed when in the advanced stage; thus, long-term clinical outcomes are poor and patients have limited treatment options. Currently, surveillance of hepatocellular carcinoma relies upon serological testing of alpha-fetoprotein levels and hepatic ultrasonography, which have low sensitivity and specificity, and are sometimes operator-dependent, respectively. Therefore, discovery of new biomarkers for early and accurate detection of hepatocellular carcinoma would be of great clinical value. Genomic and proteomic approaches are two major laboratory platforms for the identification of candidate hepatocellular carcinoma biomarkers based on profiling and validating with tumor and nontumor clinical samples. Frequently, these diagnostic markers have been found in association with genetic aberrations, protein-level alterations, post-translational modifications and immune functions. With the discovery of these biomarkers, earlier detection of hepatocellular carcinoma in high-risk subjects (e.g., cirrhosis and hepatitis carriers) becomes possible, which will enable clinicians to offer patients better clinical management and more effective treatment modalities.-
dc.languageengen_HK
dc.publisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/bmmen_HK
dc.relation.ispartofBiomarkers in Medicineen_HK
dc.titleGenomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1752-0363&volume=1&issue=2&spage=273&epage=284&date=2007&atitle=Genomic+and+proteomic+biomarkers+for+diagnosis+and+prognosis+of+hepatocellular+carcinomaen_HK
dc.identifier.emailLee, NPY: nikkilee@hkucc.hku.hken_HK
dc.identifier.emailCheung, ST: stcheung@hkucc.hku.hken_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailLuk, JMC: jmluk@hkucc.hku.hken_HK
dc.identifier.authorityCheung, ST=rp00457en_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityLuk, JMC=rp00349en_HK
dc.identifier.doi10.2217/17520363.1.2.273-
dc.identifier.pmid20477402-
dc.identifier.hkuros137272en_HK
dc.identifier.isiWOS:000252314300012-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats